

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
U.S.S.N. 10/696,770

Remarks

The present invention is directed to methods of increasing or diverting a pre-existing immune response in an individual by administering an immunity linker having binding sites that include polypeptides expressed by bacteriophages. After entry of the amendments, Claims 1-4, 7, 10, 11, 13-16 and 18 remain pending in this application. Claims 1, 14 and 18 have been amended. Support for these amendments is found at least at page 13, lines 13-20 and page 17, lines 1-22 of the specification. Claim 12 is cancelled herein. Claims 5, 6, 8, 9 and 17 have been previously canceled. Claims 19 and 20 are newly added.

No new matter has been added as a result of these amendments. Entry of these amendments is respectfully requested.

Claim Rejections under 35 U.S.C. §112, second paragraph

Claims 14 has been rejected under 35 U.S.C. §112, second paragraph as being unclear. The Applicant respectfully traverse the rejection as it applies to the amended claims.

Claim 14 has been amended to particularly point out and distinctly claim the subject matter which Applicant regards as his invention. The claims have been amended to recite that the binding sites differ in their specificity for different immune response components or their affinity for the same immune response component. Accordingly, Applicant respectfully requests withdrawal of this rejection.

Claims 11 has been rejected under 35 U.S.C. §112, second paragraph as being unclear. The Applicant respectfully traverse the rejection as it applies to the amended claims.

Claim 1 has been amended to provide antecedent basis for the term "the first bacteriophage" found in claim 11. Accordingly, Applicant respectfully requests withdrawal of this rejection.

Claim Rejections under 35 U.S.C. §112, first paragraph (written description)

Claims 1-4, 7, 10-16 and 18 are rejected under 35 USC 112, 1st paragraph for lacking written description.

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
U.S.S.N. 10/696,770

Claims 1 and 18 have been amended to recite that the first and second polypeptides are expressed by the same bacteriophage. Support for this amendment is found at least at page 13, lines 13-20 of the specification. Accordingly, Applicant respectfully requests withdrawal of this rejection.

Claim Rejections under 35 U.S.C. §112, first paragraph (enablement)

Claim 12 is rejected under 35 USC 112, 1st paragraph for lacking enablement.

Applicant has cancelled claim 12 and therefore the rejection is moot.

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
U.S.S.N. 10/696,770

RECEIVED
CENTRAL FAX CENTER

APR 17 2008

Conclusions

Applicant submits the foregoing as a full and complete response to the Non-Final Office Action mailed on January 17, 2008. The Applicant and the undersigned submits that the present claims are in condition for allowance and respectfully requests entry of the amendment since it requires no further search, and reduces the issues presented in the Office Action. Such action is hereby courteously solicited.

If the Examiner believes there are other issues that may be resolved by telephone interview, or that there are any informalities remaining in the application that may be corrected by Examiner's Amendment, a telephone call to the undersigned is respectfully requested.

No additional fees are believed to be due in connection with this response. However, should the Commissioner determine otherwise, the Applicant hereby authorizes the Commissioner to charge such fees and credit any overpayment to Deposit Account No. 11-0980.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Stephen C. MacDonald, Ph.D.
Reg. No. 60,401

KING & SPALDING LLP
1180 Peachtree Street, N.E.
Atlanta, Georgia 30309-3521
Phone: (404) 572-2715
Fax: (404) 572-5135

Date: April 17, 2008